BioSpace News Archive

NSF Funds Neocortex , a Groundbreaking AI Supercomputer, at PSC The National Science Foundation awarded $5 million to the Pittsburgh Supercomputing Center to build Neocortex, an AI supercomputer that will introduce revolutionary technologies

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocular disease Contrary to historical studies of CBD, CBDVHS was not associated with an elevation in intraocular pressure Long Beach, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address g

FDA-cleared iHEARtest™ now available free of charge to mitigate impact of COVID-19 pandemic

Applied BioMath announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualification in support of the development of Quantitative Systems Pharmacology Models for ADC projects.

The Accreditation Council for Medical Affairs (ACMA) today announced its new head of business for Asia, Yue Hu.

Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has submitted its formal application to list the Company’s common stock on the Nasdaq Capital Market. “After significantly strengthening our technology, business model, and corporate governance, to position Kraig Labs for future growth, an uplisting to the Nasdaq Capital Market is the natural evolution for the Comp

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial o

RenovoRx , an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent 15,807,011. This new patent broadly covers its unique therapeu

Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease to be Presented at the Virtual Edition of the 25 th European Hematology Association Annual Congress Poster presentation to highlight the tolerability, pharmacokinetics and pharmacodynamics of FT-4202 in Phase I clinical trials of single and multiple ascending dose cohorts of healthy subjects, Phase I clinical trials of single dose of SCD patients